Lifeward Ltd (LFWD) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Lifeward ltd   (NASDAQ: LFWD)


Lifeward Ltd's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Lifeward Ltd's ROI in the second quarter of 2026?
Lifeward Ltd recorded a cumulative net loss of $-31 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -171.91%.

Within the Healthcare sector 687 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3959 to 4173.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -24.56 % -45.48 % -55.85 % -59.24 % -52.38 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 24 22 11 14 17
Return On Investment (TTM) -171.91 % -159.11 % -125.18 % -163.57 % -125.18 %
LFWD's Overall Ranking # 4173 # 3959 # 3617 # 3670 # 3726
Seq. Investment Change TTM 10.29 % 2.21 % -12.81 % -23.25 % -20.3 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -31 -26 -20 -30 -30

LFWD Company Profile >> Back to LFWD Roi Comparisons >> See Annual LFWD Return On Investment



Return On Investment LFWD's Ranking
Within: No.
Industry # 161
Sector # 688
Overall # 4173

Return On Investment Statistics
High Average Low
-15.63 %
-116.35 %
-337.97 %
(Dec 31 2021)   (Dec 31 2018)



  News about Lifeward ltd Return on Investment ROI

Lifeward’s Direct Sales Strategy Promises to Boost AlterG Brand in Germany

September 24, 2024

In a significant move set to redefine their market presence, Lifeward GmbH has announced the launch of direct sales for the AlterG product line throughout Germany. This strategic shift marks a pivotal moment not only for Lifeward but also for AlterG a brand renowned for its innovative rehabilitation and performance technologies.By opting for a direct-to-consumer model, Lifeward aims to enhance its margin performance while simultaneously maximizing revenue streams from AlterG products. This new sales approach is expected to furnish Lifeward with greater control over its operations, allowing it to respond more swiftly to market demands and consumer preferences. As the health and fitness sector continues to evolve, establishing a direct line with customers may significantly enrich the brand’s visibility and consumer engagement.

nnLifeward Appoints Dr. Keith E. Tansey and Launches AlterG NEO to Transform Spinal Injury Rehabilitationnn,

September 10, 2024


In a move that underscores its commitment to pioneering advancements in spinal injury treatment and rehabilitation technology, Lifeward has made two significant announcements set to shape the landscape of healthcare. The appointment of Dr. Keith E. Tansey as Consulting Director of Clinical Research and the introduction of the AlterG NEO device are indicative of Lifeward s dedication to bridging cutting-edge research with transformative rehabilitation solutions.


A Leader in Spinal Injury Research
Dr. Keith E. Tansey, a distinguished past president of the American Spinal Injury Association, joins Lifeward with over three decades of extensive experience in the fields of spinal cord injury research and treatment. As a practicing physician, professor, and research scientist, Dr. Tansey s expertise is well-regarded in the medical community. His appointment is expected to bring forth a new era in Lifeward’s clinical research initiatives, enhancing the company’s ability to develop and refine treatments that address the complex challenges faced by individuals with spinal cord injuries.

Exoskeleton Evolution: Lifeward Takes the Lead Amidst Medicare Collaborations and Competitor Setbacks

April 1, 2024

An Exoskeleton Revolution: Lifeward CEO Addressing Medicare Payment Rate and Collaboration Challenges with CMS
In a recent open letter to shareholders, the CEO of Lifeward, a leading exoskeleton manufacturer, discussed the progress made towards finalizing the Medicare payment rate for their latest generation of ReWalk Exoskeleton. The letter shed light on the challenges faced by the company in collaborating with the Centers for Medicare and Medicaid Services (CMS) to determine the payment rate, with a focus on commercial transaction values.
The letter comes at a crucial time for Lifeward, as their competitor, Rewalk Robotics Ltd, reported a cumulative net loss of $-16 million in the 12 months leading up to the fourth quarter of 2023. This resulted in a negative return on investment (ROI) of -28.43%, reflecting the financial difficulties encountered by the company.





Financial Statements
Lifeward Ltd's II. Quarter Investments $ 24 Millions LFWD's Balance sheet
Lifeward Ltd's II. Quarter Income $ -12 Millions Quarterly LFWD's Income Statement
LFWD's Income by Division See LFWD's Income by Division


LFWD Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 11 21 56 70 91
Y / Y Investment Growth -44.93 % -62.68 % -20.13 % -23.32 % 292.61 %
Net Income in Millions 20 -29 -22 -20 -13
Y / Y Net Income Growth - - - - -
Annual Return On Investment 173.74 % -139.14 % -39.71 % -28.04 % -13.99 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 173.74 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LFWD's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LFWD's Competitors
Subscribers only: Roi for Lifeward Ltd's Suppliers
Subscribers only: Return On Investment for LFWD's Customers

Other Ratios
LFWD's Roa LFWD's Inventory Turnover Ratio LFWD's Growth Rates LFWD's Dividend Statistics
LFWD's Profitability Ratios LFWD's Asset Turnover Ratio LFWD's Dividend Growth
LFWD's Roe LFWD's Valuation Ratios LFWD's Financial Strength Ratios LFWD's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-12T06:21:14+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.